Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
PR Newswire•02/11/2026•08:30 ET
0
Key Highlights
- ➤Phase 3 ACTION trial evaluates dordaviprone in newly diagnosed H3 K27M-mutant diffuse glioma
- ➤ACTION interim analysis expected in the first half of 2027
- ➤Phase 2 JZP3507 trial initiated in recurrent grade 2 or 3 meningioma
- ➤JZP3507 showed nanomolar potency in H3 G34-mutant glioma preclinical models
Expert Statements
Josh Allen, Chief scientific officer, Oncology, Jazz Pharmaceuticals
“The data being presented at SNO demonstrates Jazz's expanding commitment to scientific innovation and our progress to develop new therapies for patients facing rare and highly aggressive brain cancers.”
Josh Allen, Chief scientific officer, Oncology, Jazz Pharmaceuticals
“Building on the landmark approval of Modeyso, we are advancing the Phase 3 ACTION trial, with an interim analysis in the first half of 2027, to potentially bring this therapy to patients earlier in the disease course.”
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 PR Newswire
Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers
Get started
Create a free account to read the full story.